| 5-Fu联合HER家族靶向药物对食管癌细胞增殖影响 |
| |
| 引用本文： | 许双塔, 许建华, 郑正荣, 赵清泉. 5-Fu联合HER家族靶向药物对食管癌细胞增殖影响[J]. 中国公共卫生, 2014, 30(2): 231-233. DOI: 10.11847/zgggws2014-30-02-33 |
| |
| 作者姓名： | 许双塔 许建华 郑正荣 赵清泉 |
| |
| 作者单位： | 1.福建医科大学附属第二医院肿瘤科, 福建 泉州 362000 |
| |
| 基金项目： | 福建省教育厅科技项目（B类JA08086）;泉州市优秀人才培养专项经费（08A19）;泉州市财政局;科技局技术研究与开发项目（2009Z16） |
| |
| 摘 要： | 目的观察常规化疗药物联合表皮长因子受体（EGFR）靶向药物C225及人表皮生长因子受体-2（HER2）靶向药物trastuzumab对食管鳞状细胞癌细胞株HE-2增殖影响。方法常规化疗药物5-Fu分别与C225及trastuzumab联合应用于食管鳞状细胞癌细胞株HE-2，采用噻唑蓝法以及流式细胞仪检测不同处理组的抗肿瘤效果。结果5-Fu 联合C225作用24、48 h时，HE-2细胞增殖抑制率分别为（45.29±0.16）%、（70.63±0.10）%，明显高于5-Fu联合trastuzumab的细胞增殖抑制率（33.02±0.19）%、（50.08±0.20）%，差异有统计学意义（P<0.05）；5-Fu 联合C225作用24、48 h时，HE-2细胞凋亡率分别为（15.47±1.62）%、（26.89±1.12）%；明显高于5-Fu联合trastuzumab的细胞凋亡率（7.34±0.88）%、（15.56±0.97）%，差异有统计学意义（P<0.05）。结论EGFR信号通路上的靶向治疗药物C225可以增加5-Fu抗食管鳞状细胞癌作用。
|
| 关 键 词： | 5-Fu Her家族 靶向治疗 食管鳞状细胞癌 |
| 收稿时间： | 2013-08-19 |
Influence of 5-FU joint HER family targeted drugs on proliferation of esophageal squamous carcinoma cell |
| |
| XU Shuang-ta, XU Jian-hua, ZHENG Zheng-rong.et al, . Influence of 5-FU joint HER family targeted drugs on proliferation of esophageal squamous carcinoma cell[J]. Chinese Journal of Public Health, 2014, 30(2): 231-233. DOI: 10.11847/zgggws2014-30-02-33 |
| |
| Authors: | XU Shuang-ta XU Jian-hua ZHENG Zheng-rong.et al |
| |
| Affiliation: | 1.Department of Oncology, Second Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian Province 362000, China |
| |
| Abstract: | ObjectiveTo observe the influence of conventional chemotherapy drugs combined with epidermal growth factor receptor (EGFR) targeted drug C225 and human epidermal growth factor receptor-2 (HER2) targeted drug trastuzumab on proliferation of squamous cell carcinoma of the esophagus HE-2 cell line.MethodsMethyl thiazolyl tetrazolium bromide (MTT) assay and flow cytometry were applied to detect the effects of fluorourcil (5-FU) combined with C225 or 5-FU combined with trastuzumab on the proliferation of HE-2 cells.ResultsThe in vitro experiments showed that after the treatments of 5-Fu combined with C225 for 24 hours and 48 hours,the inhibition rate of HE-2 cell proliferation was 45.29±0.16 and 70.63±0.10,significantly higher than those of 5-Fu combined with trastuzumab(33.02±0.19 and 50.08±0.20) (P<0.05 for all).With the treatment of 5-Fu combined with C225 for 24 hours and 48 hours,the apoposis rate of HE-2 cells was 15.47±1.62% and 26.89±1.12%,significantly higher than those of treatment of 5-FU combined with trastuzumab (7.34±0.88% and 15.56±0.97%) (P <0.05 for all).ConclusionThe targeted drug C225 combined with 5-FU for EGFR pathway shows a synergistic effect on inhibition of the proliferation in HE-2 cells and the signal pathway of EGFR could be as a target for the treatment of human esophageal carcinoma. |
| |
| Keywords: | 5-FU Her family targeted therapy squamous esophageal carcinoma |
|
| 点击此处可从《中国公共卫生》浏览原始摘要信息 |
|
点击此处可从《中国公共卫生》下载全文 |
